Moderna Announces First Participants Dosed in Phase 2/3 Study of COVID-19 Vaccine Candidate in Pediatric Population
Go back to Moderna Announces First Participants Dosed in Phase 2/3 Study of COVID-19 Vaccine Candidate in Pediatric Population| Marina Biotech, Inc. (NASDAQ: MRNA) | Delayed: 102.00 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $102.00 | 52 Week High | $0.52 | |||
| Open | $102.00 | 52 Week Low | $0.08 | |||
| Day High | $102.00 | P/E | N/A | |||
| Day Low | $102.00 | EPS | $-3.80 | |||
| Volume | 6,561 | |||||
